Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line Acute Myeloid Leukemia Planned to Initiate in Mid 2020 Finalizing Animal Studies of Brincidofovir as Smallpox Medical
Transformational Transaction Provides Key Program in First-Line Acute Myeloid Leukemia with Fast Track and Orphan Drug Designations and Potential Utility as a Platform Technology Phase II Randomized Data Presented at ASCO 2019 Demonstrated Compelling Complete Response Rates,
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities – – Restructuring to Reduce Workforce by More Than 50%,
DURHAM, N.C. , May 02, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, May 9, 2019 at 8:30 a.m.
Mike Sherman Appointed Chief Executive Officer and Mike Andriole Appointed Chief Business Officer DURHAM, N.C. , April 08, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , March 05, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing
DURHAM, N.C. , March 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that Timothy Trost , Chief Financial Officer of Chimerix, will present at the Cowen and Company 39th Annual
DURHAM, N.C. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Tuesday, March 5, 2019 at 8:30 a.m.
Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019 DURHAM, N.C. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a
M. Michelle Berrey to Step Down as Chief Executive Officer DURHAM, N.C. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M.
